References
- Butler CC , HobbsFDR , GbinigieOAet al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet401(10373), 281–293 (2023).
- Levin MJ , UstianowskiA , DeWit Set al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19. N. Engl. J. Med.386(23), 2188–2200 (2022).
- Wang Q , IketaniS , LiZet al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell186(2), 279–286.e8 (2023).
- Fareh M , ZhaoW , HuWet al. Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance. Nat. Commun.12(1), 4270 (2021).
- World Health Organization . Post COVID-19 condition (long COVID) (2022). www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition#:∼:text=Definition,months%20with%20no%20other%20explanation
- Subramanian A , NirantharakumarK , HughesSet al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med.28(8), 1706–1714 (2022).
- Peluso MJ , DeeksSG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol.43(4), 268–270 (2022).
- Notarte KI , CatahayJA , VelascoJVet al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine.53, 101624 (2022).
- World Health Organization . Health inequality monitor (2023). www.who.int/data/inequality-monitor/about#:∼:text=Health%20equity%20is%20the%20absence,economic%2C%20demographic%20or%20geographic%20characteristics
- Palefsky JM , LeeJY , JayNet al. Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer. N. Engl. J. Med.386(24), 2273–2282 (2022).
- Internationl Anal Neoplasia Society . Virtual standard high resolution anoscopy course 2023 (2023). www.iansoc.org/Virtual-Srandard-HRA-Course-2023
- Landovitz RJ , DonnellD , ClementMEet al. Cabotegravir for HIV prevention in cisgender men and transgender women. N. Engl. J. Med.385(7), 595–608 (2021).
- Delany-Moretlwe S , HughesJP , BockPet al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase III, randomised clinical trial. Lancet399(10337), 1779–1789 (2022).
- Newman PA , PrabhuSM , AkkakanjanasuparP , TepjanS. HIV and mental health among young people in low-resource contexts in Southeast Asia: a qualitative investigation. Glob. Public Health17(7), 1200–1214 (2022).
- Alene KA , MurrayMB , vande Water BJet al. Treatment outcomes among pregnant patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis. JAMA Netw. Open5(6), e2216527 (2022).
- Han WM , ApornpongT , GatechompolSet al. Association of phenotypic aging marker with comorbidities, frailty and inflammatory markers in people living with HIV. BMC Geriatr.22(1), 1010 (2022).
- Shah ASV , StelzleD , LeeKKet al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation138(11), 1100–1112 (2018).
- Turkova A , WhiteE , MujuruHAet al. Dolutegravir as first- or second-line treatment for HIV-1 infection in children. N. Engl. J. Med.385(27), 2531–2543 (2021).